This brought the entity’s holdings to more than 50,000 shares. One of Harbor’s Directors, Walter (“Wally”) Walker, purchased 9,700 shares of HCDI stock at an average price of $2.78 through an entity he has voting power over, Hana Road Partners L.P. Similar to XOS, the latest insider activity doesn’t come from management. The multiyear project is a major step forward for the Company as it allows us to meet our short and long term revenue objectives, offers multiple product types, and provides for the opportunity to monetize sections of the masterplan early in the development cycle,” explained CEO Sterling Griffin, in a December 3 PR. “This project will help alleviate the residential inventory shortage in Blaine and Whatcom County, Washington, and Vancouver, British Columbia, and will significantly increase our position in these growing markets. – 3 Penny Stocks to Watch With Bullish Sentiment Right Now This month it announced plans to acquire a 997 unit master-planned community at the Washington, Canadian border for $14 million. Everything from acquisition and entitlements to construction, sales, and management are in Harbors wheelhouse. Harbor is a real estate development company involved in land development. According to data from Fintel, HCDI’s float showed a short of 17.25% when we wrote the piece. If it sounds familiar, it’s likely because it was on our list of penny stocks with high short interest. Also, during that period, the penny stock has managed to climb from under $1.70 to over $3.05. Since October 28, HCDI stock has only closed lower than it opened eight times. Shares of Harbor Custom Development have been in one of the longest uptrends we’ve seen this quarter. Kukes also owns more than 51 million shares through SK Energy LLC, according to the Form 4 filing reported this week. The purchase was made on December 6 at an average price of $1.06, bringing his direct share ownership total to more than 2.93 million. This week, company CEO Simon Kukes reported the purchase of 200,000 shares of PED stock. Looking ahead, Pedevco explained that it expects to complete two wells in its Chaveroo Field in the Permian Basin during this quarter, with the first production expected between December and January. In addition, expenses during the quarter also decreased compared to the previous year’s period. This included a boost in revenue of nearly 70% to $4.1 million compared to just $2.4 million during Q3 2020. In the most recent update regarding third-quarter performance, Pedevco discussed strong growth in oil and gas production. The company focuses on M&A and the development of energy projects in the US. has followed the industry trend after energy prices jumped on Tuesday. Thanks to lowered Omicron variant concerns, energy stocks are also heating up this week. CFO, Kevin Tan, and Directors Nishan DeSilva and Carrie Cox reported buying more than 25,000 shares in total at average prices ranging from $2.9456 to $3.0253. This week officers and directors filed a fresh round of Form 4s showing insider activity. With top-line data expected from the Phase 3 DISSOLVE program during the second half of next year, the market seems to have grown optimistic during the last few weeks. This is the company treatment candidate for chronic refractory gout using ImmTOR. The company and Swedish Orphan Biovitrum completed the enrollment for the first of two clinical studies of a phase 3 DISSOLVE program for Selecta’s SEL-212. However, this month, Selecta’s latest update may have brought a bit of optimism into the market. – Penny Stocks To Buy For Under $1 & What To Watch Right Now This obviously caused concern, which is why SELB stock slipped during November. Last month the FDA put a clinical hold on the company’s trial to obtain additional information related to the chemistry, manufacturing, and controls related to the treatment. It’s the company’s potential treatment for methylmalonic acidemia, a disease where the body cannot break down certain proteins and fats. Its SEL-302 treatment candidate was s sticking point earlier this quarter. Selecta Biosciences is developing its ImmTOR platform for tolerogenic therapies. Both have enjoyed a strong reversal from Monday’s low, which has prompted the market to pay closer attention to related names. If you look at the major industry ETFs like the IBB and XBI, you’ll see what I mean.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |